FindTrial
Sign In

nivolumab placebo

OTHER3 trials

Sponsors

Bristol-Myers Squibb

Conditions

Brain NeoplasmsBreast CancerCarcinoma, Renal Cell

Phase 3

An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)
CompletedNCT02667587
Bristol-Myers SquibbBrain Neoplasms
Start: 2016-05-09End: 2024-04-09Updated: 2025-06-18
A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney
CompletedNCT03138512
Bristol-Myers SquibbCarcinoma, Renal Cell
Start: 2017-07-07End: 2024-02-01Updated: 2024-12-18
Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
CompletedNCT04109066
Bristol-Myers SquibbBreast Cancer
Start: 2019-11-18End: 2023-12-27Updated: 2025-01-08

Related Papers

Vessel branching patterns quantified by artificial intelligence as a novel prognostic biomarker in advanced renal cell carcinoma: A post-hoc analysis of the CM914 trial.
Journal of Clinical Oncology2026-05-27
Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial.
2025-01-2144 citations
Checkpoint inhibition for early-stage hormone receptor-positive breast cancer.
2024-06-245 citations
Abstract GS01-01: Biomarker Results in High-risk Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Primary Breast Cancer Following Neoadjuvant Chemotherapy ± Nivolumab: an Exploratory Analysis of CheckMate 7FL
Cancer Research2024-05-0224 citations
Abstract CT230: Exploratory analyses of MGMT promoter methylation and PD-L1 expression from newly diagnosed glioblastoma patients in CheckMate 548 study suggest refinement in thresholds for predicting response to standard of care and nivolumab treatments
Cancer Research2024-04-05
Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: Results from Part B of the randomized, phase 3 CheckMate 914 trial.
Journal of Clinical Oncology2024-01-2913 citations
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial.
2023-09-023 citations
Adjuvant nivolumab plus ipilimumab vs placebo for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy: Subgroup analyses from the phase 3 CheckMate 914 (part A) trial.
Journal of Clinical Oncology2023-06-019 citations
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial.
2023-02-09118 citations
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated <i>MGMT</i> promoter
Neuro-Oncology2022-04-28449 citations
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated <i>MGMT</i> promoter: An international randomized phase III trial
Neuro-Oncology2022-04-14433 citations
Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143
Neuro-Oncology Advances2022-01-0162 citations
Referral and adjuvant treatment patterns after nephrectomy in high‐risk locoregional renal cell carcinoma
Cancer Medicine2021-11-093 citations
CTIM-25. A RANDOMIZED PHASE 3 STUDY OF NIVOLUMAB OR PLACEBO COMBINED WITH RADIOTHERAPY PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA WITH METHYLATED MGMT PROMOTER: CHECKMATE 548
Neuro-Oncology2021-11-0229 citations
Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial
Journal for ImmunoTherapy of Cancer2021-06-01100 citations
Perioperative therapy in renal cancer in the era of immune checkpoint inhibitor therapy.
2021-05-0118 citations
The role of nephrectomy in metastatic renal cell carcinoma in the immuno‐oncology era
British Journal of Urology2021-04-0910 citations
Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials.
2021-01-0735 citations
A phase III trial of nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2- primary breast cancer: CheckMate 7FL.
Journal of Clinical Oncology2020-05-2024 citations
A phase III, randomized, placebo-controlled trial of nivolumab or nivolumab plus ipilimumab in patients with localized renal cell carcinoma at high-risk of relapse after radical or partial nephrectomy (CheckMate 914).
Journal of Clinical Oncology2020-05-2023 citations

5 more papers not shown